Document:

Exhibit

CONFIDENTIAL

Exhibit 10.19
EXCLUSIVE  LICENSE AGREEMENT

This Exclusive License Agreement (this "Agreement "), effective as of June 30, 2015 (the "Effective Date"), is made by and between the University of Massachusetts ("UMass"), a public institution of higher education of the Commonwealth of Massachusetts as represented by its Amherst campus having an office at 715 North Pleasant Street, Amherst, MA 01003, and Metabolix, Inc. ("Metabolix "), having a place of business at 21 Erie Street, Cambridge, MA 02139.

RECITALS

WHEREAS, UMass is the owner by assignment of certain intellectual property rights relating to plants with enhanced photosynthesis developed by Dr. Danny Schnell and others at UMass ; and

WHEREAS , Metabolix is an advanced biomaterials company with an interest in developing and commercializing products that use or incorporate the above said UMass intellectual property rights, and is committed to developing, making and selling such products as reflected in the terms below, either directly or through a separate entity; and

WHEREAS, Metabolix desires to obtain an exclusive license to the above said UMass intellectual property rights, and UMass is willing to grant an exclusive license to its intellectual property rights under the following conditions so that these intellectual property rights may be developed and the benefits enjoyed by the general public; and

WHEREAS, by written notice given on May 6, 2015, Metabolix exercised its option to obtain such a license pursuant to the Option to License between the parties dated April 30, 2015; and

WHEREAS, the license that is granted in this Agreement promotes the development of publicly funded intellectual property to practical application for the public good;

NOW, THEREFORE, UMass and Metabolix agree as follows:

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

TABLE OF CONTENTS
	
		
	Part I - Definitions
	3

	Part II - Rights and Obligations
	6

	Part III - Payments and Infringement
	12

	Part IV - General Terms and Conditions
	20

	Signature Page
	27

	Exhibit A
	28

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

Part I - Definitions

I. Definitions.

1 .1 "Affiliate" means, with respect to an entity, any other entity that, directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such first entity.  For the purposes of this definition, the term "control" (including, with correlative meanings, the terms "controlled by" and "under common control with") means (i) the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance or otherwise, or (ii) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of an entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity). For purposes of this Agreement, all references to "Metabolix" shall be deemed to include Metabolix and its Affiliates unless otherwise expressly stated.

1.2. "Confidential Information" means any confidential or proprietary information furnished by one party (the "Disclosing Party") to the other party (the "Receiving Party") in connection with this Agreement that is specifically designated as confidential at the time of disclosure or within a reasonable time thereafter. However, Confidential Information excludes information which:
(a) was in the public domain prior to the time of its disclosure under this Agreement;
(b) entered the public domain after the time of its disclosure under this Agreement through means other than an unauthorized disclosure resulting from an act or omission by the Receiving Party;
(c) was already known or independently developed or discovered by the Receiving Party without use of the Confidential Information, as evidenced by contemporaneous written  documents;
(d) is or was disclosed to the Recei ving Party at any time, whether prior to or after the time of its disclosure under this Agreement, by a third party having no fiduciary relationship with the Disclosing Party and having no obligation of confidentiality with respect to the Confidential  Information; or
(e) is required to be disclosed to comply with applicable laws or regulations or with a court or administrative order, provided that the Disclosing Party receives reasonable prior written notice of the disclosure and is given the opportunity to contest such requirements iflaw or regulation so permits.

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

1.3. "Combination Product" means a Licensed Product made using a proprietary germplasm or containing at least one additional proprietary trait and/or transgenic sequence that imparts commercial value to the Licensed Product, wherein the manufacture, use, offer for sale, sale or import of such other additional proprietary germplasm(s) or additional trait(s) and/or transgenic sequence(s) alone would not infringe one or more claims under the Patent Rights.

1.4. "Field" means transgenic plant seed or plant grown therefrom or transgenic plant material developed for sale to a farmer or grower for planting in the field, excluding plant seed or plants of any primary crop species that are excluded from the Field pursuant to 3.l.3(b).

1.5. "Licensed Product" means any transgenic plant seed or plant grown therefrom or transgenic plant material developed for sale to a farmer or grower for planting in the field, which transgenic plant seed or plant grown therefrom or transgenic plant material is covered by, embodies or is derived from (in whole or in part) one or more issued or pending claims contained in the Patent Rights.

1.6. "Milestones" means the events defined as Milestones (i), (ii), (iii) and (iv) in Section 3.1.2.

1.7. "Net Sales" means the gross amount billed or invoiced on sales by Metabolix and its Sublicensees of Licensed Products, less the following: (a) customary trade, quantity, or cash discounts to the extent actually allowed and taken; (b) rebates and amounts repaid or credited whether by reason of obsolescence, rejection or return or otherwise; and (c) to the extent separately stated on purchase orders, invoices, or other documents of sale, (i) any taxes or other governmental charges levied on the prod uction, sale, transportation, delivery, or use of a Licensed Product which is paid by or on behalf of Metabolix or its Sublicensees, and (ii) outbound transportation costs prepaid or allowed and costs of insurance in transit.

Net Sales are calculated based on the final sale of the Licensed Product to an independent third party.  If  Metabolix or a Sublicensee receives non-monetary consideration for any Licensed Products, Net Sales are calculated based on the fair market value of that consideration.  If Metabolix or its Sublicensees use or dispose of a Licensed Product in the provision of a commercial service, the Licensed Product will be considered as sold and the Net Sales will be calculated based on the sales price of such Licensed Product to an independent third party during the same Royalty Period or, in the absence of such sales, on the fair market value of such Licensed Product as determined by the parties in good faith.

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

1.8. "Patent Rights" means the United States patents and patent applications listed on Exhibit A and (a) any divisionals or (b) continuations thereof, and (c) any continuation-in-part  of any of the foregoing to the extent the claims are directed to subject matter described therein as well as (d) any patents issued on these patent applications and (e) any reissues or reexaminations of the patents, and any foreign counterparts to any of the foregoing.  The parties shall periodically amend Exhibit A to include any additional Patent Rights as defined above that arise; provided that such additional Patent Rights shall be included in the license granted hereunder, even if Exhibit A is not so amended.

1.9. "Royalty Period" means the partial calendar quarter commencing on the date on which the first Licensed Product is sold or used and every complete or partial calendar quarter thereafter during which either (a) this Agreement remains in effect or (b) Metabolix has the right to complete and sell work-in-progress and inventory of Licensed Products pursuant to Section 8.6.

1.10. "Sublicense" means any agreement of any kind or combination of agreements of any kind pertaining to Licensed Products that singly or in combination (i) include a grant of the right under the Patent Rights to make, use, offer for sale, sell and/or import one or more Licensed Products, (ii) provide freedom from suit for infringement of the Patent Rights, or (iii) an option  or other future right to obtain either of the foregoing.

1.11. "Sublicense Income" means payments or other value that Metabolix receives from a Sublicensee in consideration for the Sublicense, including without limitation option fees, upfront fees, license fees, equity, release of debt, milestone payments, and license maintenance fees, but excluding the following payments: (a) payments made for purchase of equity, to the extent they do not exceed the fair market value of such equity at the time purchase occurs, (b) payments specifically committed to discreetly budgeted  direct and indirect costs of specific and defined projects for the development of Licensed Products, commercially reasonable written documentation of which shall be provided to UMass at the time any such exclusion is sought, and (c) Sublicensee Royalties. For purposes hereof, "Sublicensee Royalties" means royalties paid to Metabolix by a Sublicensee with respect to Sublicensee Net Sales that are subject to the running royalty payable by Metabolix to UMass as set forth in Section 4.4.

1.12. "Sublicensee" means any permitted non-Affiliate sublicensee of the rights granted Metabolix under this Agreement , as further described in Section 2.2.

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

Part II- Rights and Obligations

2. Grant of Rights.

2.1. License Grant.  Subject to the terms and conditions of this Agreement and to the rights set forth in Section 2.3 below, UMass grants to Metabolix an exclusive, worldwide, royalty-bearing  license under the Patent Rights to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Field.

2.2. Sublicenses. Metabolix may grant Sublicenses of its rights under Section 2.1 with the prior written consent of UMass, which consent may not be unreasonably withheld or delayed. All Sublicenses executed by Metabolix shall be consistent with the terms of this Agreement and expressly bind the Sublicensee to the applicable terms of this Agreement. Metabolix shall promptly furnish UMass with a fully executed and unredacted copy of all Sublicenses, which shall be treated as Confidential Information of Metabolix and UMass shall provide any assurances of confidentiality reasonably requested by Sublicensee. Upon any termination of this Agreement, any Sublicenses granted by Metabolix to Sublicensees in accordance with this Agreement shall survive. Any surviving Sublicenses shall be assigned to UMass as direct licensor to the Sublicensee, with whatever modifications may be necessary to reflect the end of Metabolix's involvement, the scope of the Patent Rights, and UMass' status as a tax-exempt educational and research institution and an agency of the Commonwealth of Massachusetts.

2.3. Retained Rights.

(a) UMass. UMass retains the right to make and use the inventions claimed in the Patent Rights for academic research and teaching purposes, without payment of compensation to Metabolix .  UMass may license its retained rights under this Section to the inventors of same, other UMass faculty, postdocs,  students and collaborators, and any non-for-profit  employers of the foregoing as UMass may consider necessary to allow academic research and education to be continued.

(b) Federal Government.  The Federal Government has funded research leading to the inventions claimed in the Patent Rights, and therefore this Agreement and the grant of any rights in Patent Rights are subject to and governed by federal law as set forth in 35 U.S.C. §§ 200-211 and the regulations promulgated  thereunder, as amended, or any successor statutes or regulations.  Metabolix acknowledges 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

that these statutes and regulations reserve to the federal government a royalty-free, non-exclusive,  non-transferable  license to practice any govemment­ funded invention claimed in the Patent Rights and requires Metabolix to comply with the United States manufacturing obligation of Section 3.4(c).  Ifany term of this Agreement  fails to conform with those laws and regulations, the relevant term is an invalid provision and shall be modified by the parties pursuant to Section l0.7.

2.4. Option Right. Under the Intellectual Property Rights Agreement effective June 1, 2012, between UMass, Metabolix, Inc., The Regents of the University of California (Berkeley), and Washington State University, Metabolix, Inc. has first option to negotiate for an exclusive license to UMass inventions developed under ARPA-E award grant no. DE-AR0000200 . The parties acknowledge that should additional UMass inventions arise under ARPA-E grant no. DE­ AR0000200 which cannot be practiced without infringing the Patent Rights, it would be common practice to add such inventions to the existing license agreement rather than negotiate separate license agreement(s). The parties also agree that it would be unusual for a licensee to pay multiple additive royalties if a Licensed Product is covered by more than one patent in the same patent family.  For purposes of clarity, the aforementioned acknowledgement and agreement in no way obligates UMass to enter into an agreement with Metabolix that would provide for the licensing of such inventions to Metabolix, especially under terms that would not represent a fair market value for the inventions.

3. Metabolix's Obligations Relating to Commercialization.

3.1. Commercialization Requirements. Metabolix shall use diligent efforts, or shall cause its Sublicensees to use diligent efforts, to develop Licensed Products throughout the Field and to introduce such Licensed Products into the commercial market.  Thereafter, Metabolix or its Sublicensees shall make such Licensed Products reasonably available to the public.  Specifically, Metabolix shall fulfill the following obligations:

3.1.1 Reporting.   Within sixty (60) days after the end of each calendar year, Metabolix shall furnish UMass with a written report on the progress of Metabolix's research and development, business development, manufacturing and marketing efforts during the prior year, which report shall include all information reasonably necessary for UMass to determine if the Milestones have been met by the Milestone Dates. The report shall also contain a discussion of intended efforts and sales projections for the current year.

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

3.1.2 Milestones.  Metabolix shall fulfill the following Milestones by the dates set forth below ("Milestone Dates"):

	
		
	Milestone
	Milestone Date

	(i)  Raise a minimum of [***]
	Within [***] of the Effective Date

	(ii)  Create at least [***] viable transgenic plant strain for regulatory approval of at least one crop species selected from [***] expressing the transgene(s) of the Patent Rights
	Within [***] of the Effective Date

	(iii) Complete a multi-site field demonstration of a crop species selected from [***] expressing the transgene(s) of the Patent Rights
	Within [***] of the Effective Date

	(iv)  File for a [***] regulatory approval of a crop species selected from [***] expressing the transgene(s) of the Patent Rights
	Within [***] of the Effective Date

3.1.3 Consequences.

(a) lf UMass determines that Metabolix has failed to achieve a Milestone by the relevant Milestone Date, UMass shall furnish Metabolix with written notice of the determination. Within [***] days thereafter Metabolix will either (i) fulfill the relevant obligation or (ii) provide UMass with commercially reasonable evidence of an unforeseen, reasonable and good-faith business or technical difficulty that has caused the delay. Provided that Metabolix has made  such a showing, UMass and Metabolix will negotiate in good faith to reasonably adjust the Milestone Date to allow Metaboli x to overcome such difficulty, and also adjust downstream Milestone Dates as reasonably warranted. If within [***] days after such written notice Metabolix and UMass are unable to reach agreement on any such adjustments, or reach agreement whether such adjustment(s) are justified , the unresolved issues will be considered in dispute, and will be resolved in accordance with the dispute resolution provisions in Section 9. Metabolix's failure to achieve any Milestone by the Milestone Date for same, followed by Metabolix's failure to timely provide the required showing, will constitute a breach of this Agreement; and UMass will have the right, but not the obligation, to terminate this Agreement in accordance with the termination provisions set forth below in Section 8.3.

(b) Should Metabolix fail to develop or begin implementing a plan to commercialize a primary crop species within [***] after the Effective Date, then upon written notice from UMass to Metabolix, such primary crop species will thereafter be excluded from the Field.

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

3.2. Indemnification.

(a) Indemnity. Metabolix shall indemnify, defend, and hold harmless UMass and its trustees, officers, faculty, students, employees, and agents and their respective successors, heirs and assigns (the "Indemnitees"), against any liability, damage, loss, or expense (including reasonable attorney's fees and expenses oflitigation) incurred by or imposed upon any of the Indemnitees in connection with any claims, suits, actions, demands orjudgments arising out of any theory of liability (including without limitation actions in the form of tort, warranty, product liability, strict liability, or infringement of third party intellectual property rights), regardless of whether the action has any factual basis, arising out of or related to the exercise of any rights granted under this Agreement.  However, indemnification does not apply to any liability, damage, loss, or expense to the extent directly attributable to (i) the grossly negligent activities or intentional misconduct of the Indemnitees or (ii) the settlement of a claim, suit, action, or demand by Indemnitees without the prior written approval of Metabolix.

(b) Procedures.  The lndemnitees shall provide Metabolix with prompt written notice of any claim, suit, action, demand, orjudgment  for which indemnification  is sought under this Agreement.  Metabolix agrees, at its own expense, to provide attorneys reasonably acceptable to UMass to defend against any such claim.  The lndemnitees shall cooperate fully with Metabolix in the defense and will permit Metabolix to conduct and control the defense and the disposition of the claim, suit, or action (including all decisions relative to litigation, appeal, and settlement), except that Metabolix will not agree to any limiting interpretation of any Patent Rights patent or patent application without the prior written consent of UMass.  However, any Indemnitee may retain its own counsel, at the expense of Metabolix, if representation of the Indemnitee by the counsel retained by Metabolix would be inappropriate because of actual or potential conflicts in the interests of the Indemnitee and any other party represented by that counsel.  Metabolix agrees to keep UMass informed of the progress in the defense and disposition of the claim and to consult with UMass regarding any proposed settlement.

(c) Insurance. Commencing on the Effective Date, Metabolix shall maintain insurance that is reasonably sufficient to fulfill its obligations under this Agreement, including without limitation workers' compensation insurance with statutory limits as required by law, and commercial general liability insurance with coverage of not less than one million dollars ($1,000,000.00) for any single occurrence and three million dollars ($3,000,000.00) in the aggregate, which shall include without limitation product liability coverage. Metabolix shall provide UMass with written evidence of insurance. 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

Such insurance shall list UMass as a named insured and additional insured.

3.3. Marking of Licensed Products.  To provide notice of any and all applicable Patent Rights and in accordance with 35 U .S.C. §287 and as required in any other country, Metabolix shall mark and shall cause its Sublicensees to mark all Licensed Products that are manufactured or sold under this Agreement to the extent commercially feasible and consistent with prevailing business practices.

3.4. Compliance with Law. Metabolix shall comply with, and shall ensure that its Sublicensees comply with, all local, state, federal, and international laws and regulations relating to the development, manufacture, use, sale, and importation of Licensed Products . Metabolix expressly agrees to comply with the following:

(a) Metabolix or its Sublicensees shall obtain all necessary approvals, where required, from United States Govenunent agencies and any similar governmental  authorities of any foreign jurisdiction  in which Metabolix or Sublicensee intends to make, use, sell, or import Licensed  Products.

(b) Metabolix and its Sublicensees shall comply with all United States laws and regulations controlling the export of commodities and technical data, including without  limitation all Export Administration  Regulations of the United  States Department  of Commerce. Among other things, these laws and regulations prohibit or require a license for the export of certain types of commodities and technical data to specified countries.  Metabolix hereby gives written assurance that it will comply with and will cause its Sublicensees to comply with all United States export control laws and regulations, that it bears sole responsibility for any violation of those laws and regulations by itself or its Sublicensees, and that it will indemnify, defend, and hold the Indemnities harmless (in accordance with Section 3.2) for the consequences of any violation.

(c) The inventions claimed in the Patent Rights have been partially funded by the United States government. To the extent required by applicable laws and regulations, inter alia 35 U.S.C. §§ 200-211 , Metabolix agrees that any Licensed Products used or sold in the United States will be manufactured substantially in the United States or its territories . Current law provides that if domestic manufacture is not commercially feasible under the circumstances, UMass may seek a waiver of this requirement from the relevant federal agency on behalf of Metabolix.

3.5. Patent Tern Extension.  Metabolix  hereby agrees that in the event one or more Licensed 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

Product is subject to a regulatory review period before its commercial marketing and use (a "Regulated Licensed Product"), the term of the Patent Rights will be extended in accordance with 35 U.S.C. § 156.  Metabolix agrees to keep UMass apprised of progress toward regulatory approval, will notify UMass immediately upon approval, and will provide UMass with all information and assistance needed to file a request for patent term extension.  Metabolix acknowledges that such extensions are time critical, and that extension applications must be filed within sixty (60) days after regulatory approval or the right to extend is irrevocably lost. 
Metabolix acknowledges that it will be liable to UMass at law for failure to so extend.

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

Part III -Payments and Infringement

4. Consideration for Grant of Rights.
In partial consideration of the rights and license granted Metabolix under this Agreement, Metabolix agrees to pay each of the following:

4.1. License Fee.  Within thirty (30) days of the Effective Date, Metabolix shall pay to UMass a license fee of fifty thousand dollars ($50,000.00).  The license fee payment  is nonrefundable and not creditable against any other payments due to UMass under this Agreement.

4.2. Milestone Payments. Metabolix shall pay UMass the following milestone payments within thirty (30) days after the occurrence of each listed event:

	
		
	Payment Event
	Amount

	Milestone (iv) and each additional filing for regulatory approval of a crop species expressing the transgene(s) of the Patent Rights
	For each such crop species, a one-time payment of [***] Dollars [***]

	Obtaining regulatory approval of a crop species expressing the transgene(s) of the Patent Rights
	For each such crop species, a one-time payment of [***] Dollars [***]

These milestone payments are nonrefundable and are not creditable against any other payments due to UMass under this Agreement.

4.3. Base Royalty on Metabolix Net Sales. Metabolix shall pay to UMass a royalty of [***] percent [***] of Metabolix Net Sales, subject to adjustments as provided in Sections 4.7 and 4.8. However, in no event will royalties to UMass under this Section 4.3 be reduced below [***] percent [***] of Metabolix Net Sales for any reason.

4.4. Royalties on Sublicensee Net Sales. Metabolix shall pay to UMass a royalty no less than [***] percent [***] of each Sublicensee's Net Sales, irrespective of what such Sublicense's royalty obligations to Metabolix may be, and even if Metabolix receives no Sublicensee Royalties from a Sublicensee. If  Metabolix receives a Sublicensee Royalty greater than [***] percent [***] of a Sublicensee's Net Sales, then the UMass royalty on Sublicensee Net Sales will be [***] percent [***] of such Sublicensee's Net Sales, plus an additional percentage of Sublicense Royalties over [***] percent 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

[***] depending on when the applicable Sublicense is executed and according to the following formula:

	
		
	Sublicense Executed:
	For Sublicense Royalties greater than [***] percent [***] Metabolix shall pay UMass:

	Prior to the achievement of Milestone (i)
	[***] plus [***] percent [***] of Sublicensee Royalties greater than [***]

	After achievement of Milestone
(i) but before the achievement of Milestone (ii)
	[***] plus [***] percent [***] of Sublicensee Royalties greater than [***]

	After the achievement of Milestone (ii) but before the achievement of Milestone (iii)
	[***] plus [***] percent [***] of Sublicensee Royalties greater than [***]

	After the achievement of Milestone (iii)
	[***] plus [***] percent [***] of Sublicensee Royalties greater than [***]

Neither Sublicensee Net Sales nor Sublicensee Royalties are subject to adjustment as provided in Sections 4.7 and 4.8.

4.5. Sublicense Income.
(a) UMass Share of Sublicense Income.  Metabolix shall pay UMass a percentage of Sublicense Income according to the following schedule:

	
		
	Execution of Sublicense
	Percent of Sublicense Income

	Prior to the achievement of Milestone (i)
	[***] Percent [***]

	After the achievement of Milestone (i) but prior to the achievement of Milestone (ii)
	[***] Percent [***]

	After the achievement of Milestone (ii) but prior to the achievement of Milestone (iii)
	[***] Percent [***]

	After the achievement of Milestone (ii i)
	[***] Percent [***]

The parties acknowledge that the sliding scale of UMass' share of Sublicense Income reflects the expectation that Metabolix's intellectual property will over time constitute an increasing proportion of the intellectual property rights to be granted in a Sublicense.  For their mutual convenience, the parties agree that the sliding scale provides consideration for this and all other factors whatsoever.  Sublicense Income will not be subject to apportionment or reduction of any kind for any reason prior to 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

calculation of UMass' share except as provided in Section 4.5(b) below.

(b) Excluded  Research and Development Support.  In the event that Metabolix requests an exclusion from Sublicense Income for Sublicensee development  cost payments as provided in Section 1.11(b), the parties will negotiate in good faith to sub-contract research activities to UMass in an amount equal to the sliding scale percentages of  clause 4.S(a) above multiplied by the excluded amounts; provided UMass can perform research activities commensurate with the goals and timelines under which Metabolix receives such funding.

4.6. Minimum Annual Royalty.  Metabolix shall make the following minimum annual royalty payments to UMass:

	
		
	Calendar Year
	Amount

	[***]
	[***]

	[***] and [***]
	[***]

	[***] and thereafter
	[***]

If the total royalties calculated under Section 4.3 and 4.4 and the Sublicense Income under 4.5(a), for any year during the term of the Agreement are less than the minimum amount shown above for such year, Metabolix shall pay UMass the difference between (i) the actual royalties paid pursuant to Sections 4 .3, 4.4 and 4.5(a), and (ii) the required minimum annual royalty for that year.  Such payment will be due within sixty (60) days following each December 31 during the term of the Agreement.

4.7. Anti-stacking Deduction.  In the event that Metabolix is legally required to make running royalty payments to one or more third parties for license(s) of third party intellectual property rights necessary or useful to making, using, offering for sale, selling or importing a given Licensed Product, Metabolix may deduct up to two-thirds of such third-party royalties from any running royalty payments that are due to UMass under Section 4.3 on Metabolix Net Sales of such Licensed Product in the same Royalty Period.  However, in no event will royalties to UMass be less than [***] percent [***] of Net Sales. Such deduction cannot be taken together with a Combination Product royalty adjustment.  This provision does not apply to the royalties payable on Sublicensee Net Sales under Section 4.4.

4.8. Royalty Adjustment  for Combination Product.  Royalties payable under Section 4.3 on 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

Metabolix Net Sales of Combination Products will be reduced as follows.  The royalty shall equal (i) the royalties otherwise payable on such Net Sales, multiplied by (ii) a factor of [***], where [***] is the [***] sales price of the Combination Product, and [***]  is the sum of the [***] sales price of all other transgenic sequences contained in a given Combination Product that impart a commercially valuable crop trait, when such sequences are sold separately from the Licensed Product at the time such Licensed Product sales are made. The aforementioned [***] sales price of transgenic sequences shall be calculated as the difference between [***] sales price of plants or seed with and without such transgenic sequences. However, in no event will royalties to UMass under Section 4.3 be reduced below [***] percent [***] of Combination Product Net Sales for any reason. Such adjustment cannot be made together with an anti-stacking deduction under Section 4.7 above. Ifthe adjustment factor above cannot be calculated for any reason (e.g. transgenic seed not sold separately), the parties will negotiate in good faith an alternative mechanism for an equitable adjustment of the running royalties payable on Metabolix Net Sales of the Combination Products. This provision does not apply to the royalty on Sublicensee Net Sales.

5. Royalty Reports; Payments; Records.

5.1. First Sale.  Metabolix shall report to UMass the date of first commercial sale of each Licensed Product within thirty (30) days after occurrence in each country.

5.2. Reports and Payments .  Within sixty (60) days after the conclusion of each Royalty Period, Metabolix shall deliver to UMass a report detailing Metabolix's method of calculation of the amount of license fees and royalties and the UMass share of any Sublicense Income owed. Such report will at a minimum provide cumulative sales amounts for each Licensed Product sold during the Royalty Period and will detail Metabolix's calculation of payments owed.  Ifroyalties are paid on sales by a Sublicensee, Metabolix will provide UMass with copies of such Sublicensee's sales reports.   Ifno royalties or license fees are due to UMass for any Royalty Period, the report shall so state.  Concurrent with this report, Metabolix shall remit to UMass any payment due for the applicable Royalty Period.

5.3. Records.  Metabolix shall maintain and sha11 cause its Sublicensees to maintain complete and accurate records of Licensed Products that are made, used, sold, or imported under this Agreement and any amounts payable to UMass hereunder, which records shall contain sufficient information to permit UMass to confirm the accuracy of any reports delivered to UMass under Section 5.2.  The relevant party shall retain records relating to a given Royalty Period for at least three (3) years after the conclusion of that Royalty Period, during which time UMass shall have the right, at its expense, to cause its internal 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

accountants or an independent, certified public accountant to inspect records during normal business hours for the sole purpose of verifying any reports and payments delivered under this Agreement.  Metabolix shall pay to UMass any underpayment hereunder within thirty (30) days after the accountant delivers the results of the audit.  If any audit performed under this Section reveals an underpayment  in excess of ten percent (10%) in any Royalty Period, Metabolix shall bear or reimburse to UMass the full cost of the audit.  UMass may exercise its rights under this Section only once every year and only with reasonable prior notice to Metabolix.

5.4. Method of Payment.  All payments under this Agreement should be made to the "University of Massachusetts" in United States dollars and sent to the address identified below. All currency corrections will be made using the final exchange rate listed in The Wall Street Journal for the Royalty Period, and exchange fees if any will be borne by Metabolix.  Each payment should reference this Agreement and identify the obligation under this Agreement that the payment satisfies.

Office of Technology Commercialization  and Ventures
University of Massachusetts
225 Franklin  Street, 12th Floor
Boston, MA 02110
Attention:  Executive Director, OTCV

6. Patents and Infringement.

6.1. Responsibility  for Patent Rights.  As of the Effective Date, UMass has primary responsibility at the expense of Metabolix for the preparation, filing, prosecution, and maintenance of all Patent Rights, using patent counsel reasonably acceptable to Metabolix. UMass shall consult with Metabolix as to the preparation,  filing, prosecution, and maintenance of all Patent Rights reasonably prior to any deadline or action with the United States Patent & Trademark Office or any foreign patent office and shall furnish Metabolix with copies of relevant documents reasonably in advance of consultation. UMass will instruct its counsel to communicate directly with patent counsel for Metabolix, and to accept any suggestions or revisions that would tend to support or expand the scope of claims sought.  However, any actions or revisions that would tend to narrow the scope of claims sought would be subject to approval by UMass. Provided that Metabolix has timely paid Patent Expenses under Section 6.3 and has not elected to cease payment, UMass will not abandon any patent or patent application comprising the Patent Rights without 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

Metabolix 's written approval. However, UMass will have no obligation to file foreign patent applications unless Metabolix so requests in writing at least 30 days prior to the deadline for such filings.

6.2. Cooperation.  Metabolix shall cooperate fully in the preparation, filing, prosecution, and maintenance of all Patent Rights.  Cooperation includes, without limitation, (a) promptly executing all papers and instruments or requiring employees of Metabolix to execute papers and instruments as reasonable and appropriate to enable UMass to file, prosecute, and maintain Patent Rights in any country; and (b) promptly informing UMass of matters that may affect the preparation , filing, prosecution , or maintenance of Patent Rights.

6.3. Payment of Patent Expenses.

(a) Within thirty (30) days after UMass invoices Metabolix, Metabolix shall reimburse UMass for all patent-related expenses incurred on or after the Effective Date by UMass pursuant to Section 6.1.  Alternatively, at UMass' option, UMass may direct its counsel to bill Metabolix directly for some or all of such patent-related expenses, and Metabolix hereby agrees that in such case UMass will continue to be the sole client of such counsel, and that Metabolix will not be a client.  In its discretion, UMass may obtain an estimate of significant upcoming patent expenses from the patent counsel and, following thirty (30) days prior written notice to Metabolix, Metabolix shall remit advance payment of those expenses to the retainer account of the patent counsel; provided that Metabolix shall not be require to prepay more than three (3) months of estimated expenses.  Metabolix may elect, upon sixty (60) days written notice to UMass, to cease payment of the expenses associated with obtaining or maintaining patent protection for one or more Patent Rights patents or patent applications in one or more countries.   IfMetabolix elects to cease payment of any patent expenses, Metabolix  loses all rights under this Agreement with respect to such Patent Rights and UMass shall be free to license same to third parties. UMass will be under no obligation to pay any patent costs that Metabolix declines to pay.

6.4. Infringement  and Patent Challenges.

(a) Notification  of Infringement.  Each party agrees to provide written notice to the other party promptly after becoming aware of any infringement of the Patent Rights.

(b) Metabolix's Right to Prosecute.   As long as Metabolix remains the only licensee of the Patent Rights in the Field, Metabolix may, under its own control and at its own expense, prosecute any 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

third party infringement of the Patent Rights in the Field and defend the Patent Rights in any declaratory judgment  action brought by a third party which alleges  invalidity, unenforceability, or non-infringement of the Patent Rights, including pre- or post­ grant review or reexamination in the United States Patent and Trademark Office.  Prior to commencing any action, Metabolix shall consult with UMass and shall consider the views of UMass regarding the advisability of the proposed action and its effect on the public interest.  In the event UMass becomes a party to such case at Metabolix 's request or in response to a court order that UMass is an essential party, UMass will be represented by its own counsel at Metabolix's expense, and such counsel will work with Metabolix's counsel to promote common interests in such matter.  Metabolix may not enter into any settlement, consent judgment,  or other voluntary final disposition of any infringement action under this Subsection without the prior written consent of UMass, which consent may not be unreasonably withheld or delayed. Notwithstanding the foregoing, UMass will be under no obligation to consent to any express or implied limiting interpretation of any Patent Rights patent or patent application.

(c) Distribution of Recovery.  Any recovery obtained in an action under Subsection 6.4(b) shall be distributed as follows: (i) each party shall be reimbursed  for any expenses incurred in the action (including the amount of any royalty payments withheld from UMass as described below); (ii) All remaining damages will be shared equally between Metabolix and UMass. Metabolix may offset a total of fifty percent (50%) of any expenses incurred under Subsection 6.4(b) against any royalty payments due to UMass under this Agreement, including without limitation minimum royalties under Section 4.6 and sublicensing payments under Section 4.5.  However, royalty payments under Section 4 may never be reduced by more than fifty percent (50%) in any Royalty Period, and the royalty payments withheld shall be reimbursed to UMass from the recoveries obtained in the action, if any, as set forth in clause (c)(i) above.

(d) Reimbursement of UMass Costs. With respect to any action contemplated or initiated by Metabolix pursuant to Subsection 6.4(b), Metabolix shall indemnify, defend and hold harmless the lndemnitees (in accordance with Section 3.2) from and against any reasonable costs, expenses, or liability (including reasonable attorneys' fees and expenses of litigation) that UMass may incur in connection with its support or participation in the action.

(e) UMass Right to Pursue Infringers and Defend the Patent Rights.   If Metabolix fails to initiate an infringement action within a reasonable time after it first becomes aware of the basis for the action, or to answer a declaratory judgment  action and file compulsory counter claims wi thin a 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

reasonable time after the action is filed, UMass may prosecute the infringement and answer the declaratory judgment  action under its sole control, and any recovery obtained shall be retained  by UMass.   IfUMass initiates an action under this Subsection 6.4(e), UMass shall keep Metabolix reasonably informed of material actions undertaken by UMass, except in the event of a declaratory judgment  action brought by Metabolix.

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

Part IV - General Terms and Conditions

7. Confidential Information and Publicity.

7.I Confidential Information.

(a) Designation. Confidential Information that is disclosed in writing shall be marked with a legend indicating its confidential status (such as, "Confidential" or "Proprietary"). Confidential Information that is disclosed orally or visually shall be documented in a written notice prepared by the Disclosing Party and delivered to the Receiving Party within thirty (30) days of the date of disclosure.  The notice shall summarize the Confidential Information disclosed to the Receiving Party and reference the time and place of disclosure.

(b) Obligations. For a period of five (5) years after disclosure of any Confidential Information, the Receiving Party shall (i) maintain such Confidential Information in confidence, except that the Receiving Party may disclose or permit the disclosure of any Confidential Information to its trustees or directors, officers, employees, attorneys, consultants, and advisors (collectively, "Representatives") who are obligated to maintain the confidential nature of Confidential Information and who need to know Confidential Information for the reasonable business purposes of the Receiving Party; (ii) use Confidential Information solely for the purposes of this Agreement; and (iii) allow its Representatives to reproduce the Confidential Information only to the extent necessary for the purposes of this Agreement, with all reproductions being Confidential Information.

(c) Ownership and Return.  The Receiving Party acknowledges that the Disclosing Party (or a third party entrusting its own information to the Disclosing Party) owns the Confidential Information in the possession of the Receiving Party.  Upon expiration or termination of this Agreement , or at the request of the Disclosing Party, the Receiving Party shall return to the Disclosing Party all originals, copies, and summaries of documents, materials, and other tangible manifestations of Confidential Information in the possession or control of the Receiving Party, except that the Receiving Party may retain one copy of the Confidential Information in the possession of its legal counsel solely for the purpose of monitoring its obligations under this Agreement.

7.2. Publicity and Use of Name Restrictions.  Metabolix may not use the name, likeness or logo of UMass or any of its trustees, officers, faculty, students, employees, or agents, or any adaptation of their 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

names, or any terms of this Agreement in any press release or other public announcement or disclosure without the prior written consent of UMass.  The foregoing notwithstanding , Metabolix may disclose that information without the consent of UMass in any prospectus, offering memorandum, or other document or filing required by applicable securities Jaws or other applicable law or regulation, provided that Metabolix provides UMass, as soon as reasonably practicable, prior written notice of the proposed text for the purpose of giving UMass a reasonable opportunity to comment on the text.  Metabolix may only disclose factual information hereunder, and shall not use the name, likeness or logo of UMass or any employee  of UMass in a manner that reasonably could be viewed as an endorsement of a commercial product or service.

8. Term and Termination.

8.1. Term. Unless sooner terminated as otherwise provided in this Agreement, the term of this Agreement shall commence on the Effective Date hereof and shall continue in full force and effect until the expiration of the last to expire of the Patent Rights.

8.2. Voluntary Termination by Metabolix.  Metabolix may terminate this Agreement for any reason upon ninety (90) days prior written notice to UMass.

8.3. Termination  for Default.  If either party commits a material breach of its obligations under this Agreement and fails to cure that breach within sixty (60) days after receiving written notice of the breach, the other party may terminate this Agreement immediately upon written notice to the party in breach.  Failure to make any payment hereunder shall constitute a material breach.   If the alleged breach involves nonpayment of any amounts due UMass under this Agreement, Metabolix will have only one cure period applicable to such breach . Any subsequent such material breach by Metabolix will entitle UMass to terminate this Agreement immediately upon written notice to Metabolix, without the sixty-day cure period.

8.4. Termination for Patent Challenge. The parties acknowledge and agree that Metabolix is not estopped from contesting the validity or enforceability of the Patent Rights. However, Metabolix hereby agrees that if it decides to assert its right to contest the Patent  Rights, in whole or in part, that UMass shall have the right, at UMass' option, to terminate this License Agreement with respect to the contested Patent Rights by giving written notice thereof to Metabolix, which termination shall have immediate effect.  In the event UMass does not terminate, Metabolix agrees to meet its obligations hereunder, and 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

that any payments due will be made to UMass, and not diverted to escrow or otherwise; and such payment shall not be refundable for any reason.

8.5. Force Majeure. Neither party is responsible for delays resulting from causes beyond its reasonable control, including without limitation fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove those causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever the causes are removed.

8.6. Effect of Termination.  Articles 1, 7 and 9; Sections 3.2, 3.4, 5.2, 5.3, 6.3 (with respect to expenses incurred prior to the effective date of termination), 6.4, 8.6, 10.5, 10.6, any other Articles and Sections hereof which by their nature are inherently intended to survive, shall survive any termination of this Agreement. Upon the early termination of this Agreement, Metabolix and its permitted Sublicensees may complete and sell any work-in-progress and inventory of Licensed Products that exist as of the effective date of termination, provided that (a) Metabolix is current in payment of all amounts due UMass under this Agreement, (b) Metabolix pays UMass the applicable percentage of all Sublicense Income and the applicable royalty on Net Sales of Licensed Products and applicable royalties on Net Sublicensee Sales in accordance with the terms of this Agreement, and (c) Metabolix and its Sublicensees complete and sell all work-in-progress and inventory of Licensed Products within six (6) months after the effective date of termination. Upon termination for any reason other than breach by UMass, Metabolix hereby agrees to provide to UMass the right to access to files, data and procedures for regulatory approval of any Licensed Products in any country that may have been created or commenced by Metabolix during the term hereof, and agrees to license such access or sell same to any subsequent UMass licensee, on commercially reasonable terms.

9. Dispute Resolution.

9.1. Procedures Mandatory. The parties agree that any dispute arising out of or relating to this Agreement will be resolved solely by means of the procedures set forth in this Article, and that these procedures constitute legally binding obligations that are an essential provision of this Agreement.

9.2. Dispute Resolution Procedures.

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

(a) Negotiation.  In the event of any dispute arising out of or relating to this Agreement, the affected party shall notify the other party, and the parties shall attempt in good faith to resolve the matter within ten (10) days after the date of notice (the "Notice Date").  Any disputes not resolved by good faith discussions shall be referred to senior executives of each party, who shall meet at a mutually acceptable time and location within thirty (30) days after the Notice Date and attempt to negotiate a settlement.

(b) Mediation.  If the matter remains unresolved  within sixty (60) days after the Notice Date, or if the senior executives fail to meet within thirty (30) days after the Notice Date, either party may initiate mediation upon written notice to the other party, whereupon both parties shall engage in a mediation proceeding under the then current International Institute for Conflict Prevention and Resolution, Inc. ("CPR") Mediation Procedure then in effect, except that specific provisions of this Section override inconsistent provisions of the CPR Mediation Procedure.  The mediator will be selected from the CPR Panels of Neutrals.   Ifthe parties cannot agree upon the selection of a mediator within ninety (90) days after the Notice Date, then upon the request of either party, the CPR shall appoint the mediator.  The parties shall attempt to resolve the dispute through mediation until one of the following occurs: (i) the parties reach a written settlement; (ii) the mediator notifies the parties in writing that they have reached an impasse; (iii) the parties agree in writing that they have reached an impasse; or (iv) the parties have not reached a settlement within one hundred twenty (120) days after the Notice Date.

(c) Trial Without Jury.  Ifthe parties fail to resolve the dispute through mediation , or if neither party elects to initiate mediation, each party may pursue any other remedies legally available to resolve the dispute.  However, the parties expressly waive the right to a jury trial in such legal proceeding.

9.3. Preservation  of Rights Pending Resolution.

(a) Performance to Continue. Each party shall continue to perform its obligations under this Agreement pending final resolution of any dispute arising out of or relating to this Agreement. However, a party may suspend performance of its obligations during any period in which the other party fails or refuses to perform its obligations.

(b) Statute of Limitations.  The parties agree that all applicable statutes of limitation and time-based defenses (including without limitation estoppel and !aches) are tolled while the procedures set 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

forth in Subsections 9.2(a) and 9.2(b) are pending.  The parties shall take any actions necessary to effectuate this result.

10. Miscellaneous.

10.1. Representations and Warranties.  UMass represents that its employees have assigned to UMass their entire right, title, and interest in the Patent Rights and that it has authority to grant the rights and licenses set forth in this Agreement.  UMASS DISCLAIMS AND MAKES NO OTHER WARRANTIES  CONCERNING THE PATENT RIGHTS, INCLUDING  WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY  OR FITNESS FOR A PARTICULAR  PURPOSE.   SPECIFICALLY, WITHOUT LIMITATION, UMASS DISCLAIMS AND MAKES NO WARRANTY OR REPRESENTATION  (A) REGARDING THE VALIDITY  OR SCOPE OF THE PATENT RIGHTS, (B) THAT THE EXPLOITATION OF THE PATENT RIGHTS OR ANY LICENSED PRODUCT WILL NOT INFRINGE ANY PATENTS OR OTHER INTELLECTUAL PROPERTY  RIGHTS OF A THIRD PARTY, AND (C) THAT ANY THIRD PARTY IS NOT CURRENTLY INFRINGING OR WILL NOT INFRINGE THE PATENT RIGHTS.

10.2. Counterparts. This Agreement may be executed in one or more counterparts, each of which is an original, and all of which together are one instrument.

10.3. Assignment.  This Agreement may not be assigned by either party without the prior
written consent of the other party, which consent shall not be unreasonably withheld or delayed, except that Metabolix may assign this Agreement to an Affiliate or in connection with the sale, disposition or spinout of its crops research program ; a merger; or acquisition or sale of all or substantially all its business to which the Patent Rights relate to an entity which has the financial and technical capacity to satisfy Metabolix's commercialization obligations under this Agreement.

10.4. Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified only by means of a \vritten instrument signed by both parties. Any waiver of any rights or failure to act in a specific instance relates only to that instance and is not an agreement to waive any rights or fail to act in any other instance.

10.5. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts irrespective of any conflicts of law principles.

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

10.6. Notice.  Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent by recognized national overnight courier, or registered or certified mail, postage prepaid, return receipt requested, to the following addresses:

If to UMass:

Technology Transfer Office University
of Massachusetts Amherst Arnold
House, Room 232
715 North Pleasant Street
Amherst, MA  01003

Attention:    Director, TTO

If to Metabolix:

Metabolix
21 Erie Street
Cambridge, MA 02139

Attention:    Chief Scientific Officer

All notices under this Agreement are effective upon receipt.  A party may change its contact information immediately upon written notice to the other party in the marmer provided in this Section.

10.7. Severability . If any provision of this Agreement is held invalid or unenforceable for any reason, the invalidity or unenforceability does not affect any other provision of this Agreement, and the parties shall negotiate in good faith to modify the Agreement to preserve (to the extent possible) their original intent.  If the parties fail to reach a modified agreement within sixty (60) days after the relevant provision is held invalid or unenforceable, then the dispute shall be resolved in accordance with the procedures set forth in Article 9.  While the dispute is pending resolution, this Agreement shall be 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

construed as if the provision were deleted by agreement of the parties.

10.8. Entire Agreement.  This Agreement, together with the Intellectual Property Rights Agreement effective June 1, 2012, constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements or understandings between the parties relating to its subject matter.  In the event of any inconsistency between this Agreement and said Intellectual Property Rights Agreement, the provisions of this Agreement shall govern.

10.9. Headings. All headings herein are provided for convenience only, and the parties agree that such headings shall not be construed to vary, interpret or constitute part of any contract terms hereunder.

[SIGNATURE PAGE TO FOLLOW]

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

IN WITNESS WHEREOF, each party has caused this Agreement to be executed by its duly authorized representative as of the Effective Date.

	
					
	UNIVERSITY OF MASSACHUSETTS AMHERST
	 
	METABOLIX, INC.

	 
	 
	 
	 
	 

	By:
	/s/ Robert S. MacWright
	 
	By:
	/s/ Oliver P. Peoples

	Name:
	Robert S. MacWright, Ph.D., Esq.
	 
	Name:
	Oliver P. Peoples PhD.

	Title:
	Director, Technology Transfer Office
	 
	Title:
	Founder, CEO & Director

	Date:
	6/30/2015
	 
	Date:
	7/5/2015

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL

EXHIBIT A

List of Patent Rights

PCT Application No. PCT/ US2014/072347, entitled "PLANTS WITH ENHANCED PHOTOSYNTHESIS AND METHODS OF MANUFACTURE THEREOF," filed on December 24, 2014, which claims priority to U.S. Provisional Application No. 61/922, 141, filed on December 31, 2013.
Inventors: Danny Schnell, Michelle Dacosta, Mine Canaki, Bibin Palouse

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.Exhibit

SUBLEASE

THIS SUBLEASE is made as of the 16th day of September, 2016, by and between METABOLIX, INC., a Delaware corporation (“Sublandlord”), with an address of 19 Presidential Way, Woburn, Massachusetts, and CJ Research Center LLC (“Subtenant”), with an address of  3530 Wilshire Blvd., Suite 1220, Los Angeles, CA 90010, Attn: Legal Department.

RECITALS

A.    Sublandlord is the Tenant under that certain Lease Agreement with ARE-MA Region No. 20, LLC, as Landlord (“Master Landlord”), dated January 20, 2016 (the “Master Lease”), of premises located at 19 Presidential Way, Woburn, Massachusetts and more particularly described in the Master Lease (the “Premises”).

B.    Subtenant wishes to sublease from Sublandlord and Sublandlord wishes to sublease to Subtenant a portion of the Premises, subject to the terms and conditions of this Sublease.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1.Subleasing.  Sublandlord hereby subleases to Subtenant and Subtenant hereby subleases from Sublandlord the premises consisting of approximately 9,874 rentable square feet located on the third (3rd) floor of the building known as and numbered 19 Presidential Way, Woburn, Massachusetts, being a portion of the Premises located on the third (3rd) floor of said building (the “Subleased Premises”), together with (a) the right of access to the Subleased Premises in accordance with Section 1 of the Master Lease, (b) the right to exercise, in common with Sublandlord and others entitled thereto, Sublandlord’s right to use the Common Areas as defined under the Master Lease necessary or appropriate to Subtenant’s use of the Subleased Premises, including, without limitation, thirty-one (31) of the parking spaces allocated to Sublandlord under Section 10 of the Master Lease, and (c) the right to use, in common with Sublandlord, approximately 2,000 square feet (the “Shared Space”), which Shared Space is located within the Premises as shown on Exhibit A hereto, in connection with its use of the Shared Equipment (defined below), as more fully discussed in Section 10 below.  The Shared Space does not constitute a part of the Subleased Premises. 

2.    Term.  The term (“Term”) of this Sublease shall commence on the later of (i) full execution of this Sublease or (ii) the date that Sublandlord delivers to Subtenant Master Landlord’s written consent to this Sublease (the later being, the “Commencement Date”), and shall terminate on the last day of the Base Term of the Master Lease (the “Termination Date”).  Subtenant shall have no right to extend the term of this Sublease; provided, that in the event Master Landlord and Landlord agree to extend the Base Term of the Master Lease, Subtenant shall, at Subtenant’s option (exercisable in its sole discretion), have the right to extend the term of this Sublease commensurate with such extension of the Master Lease.  

3.    Master Landlord’s Consent.  The effectiveness of this Sublease and Subtenant’s and Sublandlord’s obligations hereunder shall be conditioned on and are subject to Sublandlord’s receipt of Master Landlord’s written consent to this Sublease on terms acceptable to Sublandlord and Subtenant.

4.    Base Rent.   The base rent for the Subleased Premises (the “Base Rent”) shall be $25.00 per rentable square foot of the Subleased Premises per year, which the parties agree shall be $20,570.83 per month adjusted as of each Adjustment Date as set forth in the Master Lease.  Notwithstanding the foregoing, for any period during the term of the Sublease that Sublandlord’s Base Rent is reduced by the last paragraph of Section 3(a) of the Master Lease, Subtenant’s Base Rent shall be one-third (1/3rd) of Sublandlord’s reduced Base Rent.   Base Rent shall be payable in equal monthly installments, in advance, on the first day of each and every calendar month during the term of this Sublease, to Sublandlord at Sublandlord’s address set forth above or at such other place as Sublandlord shall from time to time designate.  Base Rent for any partial month shall be pro‐rated on a daily basis.  

5.    Additional Rent.  In addition to Base Rent, Subtenant agrees to pay Sublandlord one-third (1/3) of (i) all Additional Rent for Operating Expenses (as defined in Section 5 of the Master Lease), including Taxes (as defined in Section 9 of the Master Lease), and (ii) any and all other amounts Sublandlord assumes or agrees to pay under the provisions of the Master Lease that directly serve the Subleased Premises (including, without limitation, payments to amortize the additional tenant improvement allowance as provided in Section 4(b) of the Master Lease.   In addition, Subtenant shall pay for one-third (1/3rd) of any charges for services provided to the Premises by Master Landlord, which services directly serve or benefit the Subleased Premises, and specifically billed to the Premises by Master Landlord, within thirty (30) days of receiving Master Landlord’s invoice therefor, or, if Sublandlord has previously paid the same, to Sublandlord within thirty (30) days after receiving Sublandlord’s invoice therefor, as well as any additional rent charged under the Master Lease to the extent that the additional rent arises out of any default of Subtenant under this Sublease or any damage (subject to the waiver of subrogation contained in the Insurance provision of this Sublease) caused by Subtenant or any of its employees, officers, agents, contractors or invitees, except to the extent of any default or damage caused by Sublandlord, its employees, officers, agents, contractors or invitees.  All payments of Additional Rent to Sublandlord by Subtenant as required herein shall be made as set forth in Paragraph 3 above with respect to Base Rent.  In the event any services are provided by Master Landlord that do not directly serve, in whole or in part, the Subleased Premises, Subtenant shall not be responsible for its pro-rata share of the same and, in the event any services serve only the Subleased Premises, Subtenant shall pay all of the costs of such services.

6.    Security Deposit.  Subtenant shall deposit with Sublandlord, upon full execution of this Sublease and receipt of Master Landlord’s written consent, a security deposit in the amount of $102,333.95 (the “Security Deposit”) for the performance of all of Subtenant’s obligations in this Sublease, which Security Deposit shall be in the form of a letter of credit meeting the requirements of Section 6 of the Master Lease.  Such Security Deposit will be held in accordance with the provisions of Section 6 of the Master Lease (as if references to Tenant were references to Subtenant and references to Landlord were references to Sublandlord in such 

Section). 

7.    Incorporation of Provisions.  Subtenant agrees that it will do nothing in, on or about the Subleased Premises which would result in the breach by Sublandlord of its undertakings and obligations under the Master Lease.  Except for the following provisions, this Sublease shall be subject to and on all of the terms and conditions as are contained in the Master Lease and the provisions of the Master Lease are hereby incorporated into this Sublease as if Sublandlord were the landlord thereunder and Subtenant the tenant thereunder:  

		
	•
	The defined economic terms for “Base Rent,” “Base Term,” “Premises,” “Rentable Area of the Premises,” “Tenant’s Share of Operating Expenses,” “Target Commencement Date,” “Address for Rent Payment,” and “Tenant’s Notice Address” and the like are inapplicable, except where used to reference such defined term with respect to the Master Lease;

		
	•
	Section 3(b) of the Master Lease (relating to additional rent) are applicable, as modified by the provisions of Paragraph 4 of this Sublease, except where used to reference such defined term with respect to the Master Lease;

		
	•
	Section 4(b) (relating to additional tenant improvement allowance) is   inapplicable, except where used to reference such defined term with respect to the Master Lease; 

		
	•
	The first and second full paragraphs of Section 17 (Insurance) are inapplicable;

		
	•
	Section 22 of the Master Lease (relating to assignment and subletting) is inapplicable;

		
	•
	Section 35 (Brokers) is inapplicable;

		
	•
	Exhibit C of the Master Lease (relating to Landlord’s Work), Exhibit D (Commencement Date) and Exhibit F (Tenant’s Personal Property) are inapplicable;

		
	•
	Where appropriate, references to “Landlord” in the Master Lease shall be deemed to mean “Sublandlord” hereunder and references to “Tenant” in the Master Lease shall be deemed to mean “Subtenant” hereunder, it being understood and agreed that Sublandlord will not be acting as, or assuming any of the responsibilities of, Master Landlord, and all references in the Master Lease to Landlord-provided services or Landlord insurance requirements, and any other references which by their nature relate to the owner or operator of the Building, rather than to a tenant of the Building subleasing space to a subtenant, shall continue to be references to Master Landlord and not to Sublandlord.

8.    Direct Performance.  At any time by written notice to Subtenant in advance (no less than thirty (30) days), Sublandlord may elect to require Subtenant to perform Subtenant’s obligations under this Sublease directly to Master Landlord, provided such performance directly to Master Landlord is reasonable under the circumstances and does not require Subtenant to incur additional costs or expenses greater than would be required if Subtenant were to perform such obligations to Sublandlord, Subtenant shall do so on Sublandlord’s reasonable prior written election, in which event Subtenant shall send to Sublandlord from time to time copies of all notices and other communications that it shall send to and receive from Master Landlord with respect to the Subleased Premises.  Subtenant may also perform Sublandlord’s obligations as required hereunder with respect to the Subleased Premises if directed in writing by Master Landlord and thereafter shall be released of the obligation to perform such obligations to Sublandlord until directed in writing by Master Landlord.

9.    Delivery.  Sublandlord shall deliver the Subleased Premises to Subtenant with all personal property of Sublandlord removed and in broom clean condition, except for (i) the Office Equipment (defined below), and (ii) the personal property purchased by Subtenant from Sublandlord pursuant to that certain Asset Purchase Agreement dated September 16, 2016 between Sublandlord and Subtenant.  Except as provided by the preceding sentence or as otherwise stated herein (or in the Asset Purchase Agreement), Sublandlord has made no representations, warranties or undertakings as to the present or future condition of the Subleased Premises or the fitness and availability of the Subleased Premises for any particular use.  The acceptance of the Subleased Premises by Subtenant shall constitute an acknowledgment by Subtenant that the Subleased Premises are in the condition they are required to be in by this Sublease.  Except as provided for in this Paragraph, Subtenant shall perform all work to make the Subleased Premises complete for Subtenant’s use in Subtenant’s discretion, subject to the provisions of Sections 7 and 12 of the Master Lease, as incorporated in this Sublease by reference including, without limitation, the requirement to obtain Sublandlord’s and Master Landlord’s prior written consent thereto.  Subtenant agrees it shall be responsible for the costs in connection with the performance of such work, including without limitation, the costs to (i) divide and demise the Subleased Premises from the Premises, (ii) install doors, locks and/or card strikes (or similar apparatus) to provide Subtenant adequate access to and from the Subleased Premises to the Shared Space and the main entrance of the Building and (iii) install any other improvements to the Subleases Premises necessary for Subtenant’s use, in Subtenant’s discretion, including any other security measures or devices. 

10.    Shared Space; Shared Equipment. Subtenant shall have access to the Shared Space at all times as necessary in connection with Subtenant’s operations under this Sublease to utilize that certain equipment described and depicted in Exhibit B, attached hereto and made a part hereof (the “Shared Equipment”), which Shared Equipment shall remain the personal property of Sublandlord, but shall be utilized by both Sublandlord and Subtenant, upon the terms and conditions contained herein.  

a.Shared Space.  Subtenant shall be permitted to access the Shared Space at all reasonable times to use the Shared Equipment in the manner set forth herein. 

b.Shared Equipment. Sublandlord and Subtenant shall each have the right to use the Shared Equipment in connection with each party’s respective use under the Master Lease and Sublease.   

c.Interference and Use.   Sublandlord and Subtenant each agree that it will use the Shared Equipment in a manner that will not interfere with the use of the Shared Equipment by the other party.

d.Maintenance.  Sublandlord and Subtenant each agree that it shall maintain and repair the Shared Equipment during the Term of this Sublease. In the event either Sublandlord or Subtenant determines that maintenance and/or repairs to the Shared Equipment are required, then it shall advise the other party in writing.  Thereafter, the parties shall agree in writing that such maintenance and repairs are required and shall further agree in writing as to the cost of such repairs and maintenance. Each party agrees to reimburse to the other party, respectively, an amount equal to one-half (1/2) of the cost of such maintenance and repair actually paid within thirty (30) days after receipt of an invoice including all reasonable supporting documentation, provided such costs are previously approved by all parties in writing.  Notwithstanding the foregoing, neither party shall have any obligation to reimburse the other party for any repair costs resulting from damage to the Shared Equipment caused by the negligent acts or omissions or intentional misconduct of the other party or its employees, officers, agents or contractors.  In the event the Shared Equipment are damaged by the negligent acts or omissions or intentional misconduct of Sublandlord or Subtenant, then the party which caused such damage shall repair the Shared Equipment at its sole cost and expense within thirty (30) days after the date of such damage.  In the event such party does not repair the Shared Equipment within such thirty (30) day period, then the other party (Sublandlord or Subtenant, as the case may be) may repair the Shared Equipment and the party which caused the damage shall reimburse to the other party, an amount equal to one hundred percent (100%) of the cost of such repair actually paid within thirty (30) days after receipt of an invoice including all reasonable supporting documentation.

e.Indemnity.  Each party shall indemnify and hold the other harmless against any claim of liability or loss (including reasonable attorneys’ fees and costs) from personal injury or property damage resulting from or arising out of the use and occupancy of the Shared Space or the Shared Equipment by the indemnifying party, its employees, officers, contractors, agents or invitees, excepting, however, such claims or damages as may be due to or caused by the acts or omissions of the other party, or its employees, officers, contractors, agents or invitees.

11.    Office Equipment.  Sublandlord and Subtenant acknowledge and agree that Sublandlord owns certain desks, chairs and related office equipment (the “Office Equipment”), which Office Equipment is located within the Subleased Premises and will be utilized by Subtenant throughout the Term of this Sublease. Such Office Equipment shall remain Sublandlord’s personal property during the Term of this Sublease but will be made available to Subtenant, in its “as-is” condition, for Subtenant’s use within the Subleased Premises.  Subtenant shall have the obligation to maintain such Office Equipment in reasonably good condition at 

Subtenant’s sole cost and expense.  Upon expiration or earlier termination of this Sublease, Subtenant shall not be required to remove the Office Equipment, and shall surrender the same in good, clean condition, reasonable wear and tear excepted. 

12.    Removal. Upon expiration or earlier termination of this Sublease, Subtenant shall surrender the Subleased Premises in good, broom clean condition, reasonable wear and tear excepted in accordance with Section 28 of the Master Lease. Subtenant shall not be required to remove the Office Equipment or Shared Equipment or restore the Shared Space, which obligations shall be borne by Sublandlord in accordance with Section 28 of the Master Lease.

13.    Insurance. The second full paragraph of Section 17 of the Master Lease is replaced and superseded by the following: Subtenant, at its sole cost and expense, shall maintain during the Term of this Sublease: (i) all risk property insurance with business interruption and extra expense coverage, covering the full replacement cost of all property and improvements installed or placed in the Subleased Premises by Subtenant at Subtenant's expense; (ii) worker's compensation insurance with no less than the minimum limits required by law; (iii) employer's liability insurance with such limits as required by law; and (iv) commercial general liability insurance, with a minimum limit of not less than $2,000,000 per occurrence for bodily injury and property damage with respect to the Subleased Premises. The commercial general liability insurance policy shall name Alexandria Real Estate Equities, Inc., Sublandlord and Master Landlord, its officers, directors, employees, managers, agents, invitees and contractors (collectively, "Master Landlord Parties"), as additional insureds; insure on an occurrence and not a claims' made basis; be issued by insurance companies which have a rating of not less than policyholder rating of A and financial category rating of at least Class X in "Best's Insurance Guide"; shall not be cancelable for nonpayment of premium unless thirty (30) days prior written notice shall have been given to Sublandlord from the insurer; and provide primary coverage to Sublandlord (any policy issued to Sublandlord providing duplicate or similar coverage shall be deemed excess over Subtenant's policies). Copies of such policies (if requested by Sublandlord as an additional insured, along with reasonable evidence of the payment of premiums for the applicable period, additional insured, along with reasonable evidence of the payment of premiums for the applicable period, shall be delivered to Sublandlord by Subtenant on or prior to the Commencement Date, or the date that Subtenant accesses the Subleased Premises under this Sublease, and each renewal of said insurance. Subtenant's policy may be a "blanket policy" with an aggregate per location endorsement which specifically provides that the amount of insurance shall not be prejudiced by other losses covered by the policy. Subtenant shall, at least 5 days prior to the expiration of such policies, furnish Sublandlord with renewal certificates.

14.    Rules and Regulations.  Subtenant shall abide by the Rules and Regulations from time to time established by Master Landlord under the Master Lease of which Subtenant receives prior written notice.

15.    Notices.  All notices which may or are required to be given by either party to the other under this Sublease shall be in writing and shall be personally delivered or sent by recognized commercial delivery service providing for next day delivery and a return receipt, charges prepaid, in each case addressed to the addresses of Sublandlord and Subtenant as set 

forth above or such other address as either party may indicate by advanced written notice to the other party given as provided herein.  Any such notice shall be deemed or received upon the earliest of actual delivery or receipt or refusal of delivery, as evidenced by the return receipt, if sent by one of the methods described above providing for a return receipt. 

16.    Recording.  Unless otherwise approved by Sublandlord and Master Landlord, in the event that this Sublease or a copy hereof or any notice hereof shall be recorded by Subtenant, then such recording shall constitute a default by Subtenant entitling Sublandlord to immediately terminate this Sublease, without notice or opportunity to cure such default.

17.    Brokers.  Each party represents to the other that it has not dealt with any real estate broker, finder or other person with respect to this Sublease in any manner.  Each party shall hold harmless the other party from all damages resulting from any claims that may be asserted against the other party by any broker, finder or other person with whom the indemnifying party has or purportedly has dealt.

18.    Subject to Master Lease.  This Sublease is subject and subordinate to the Master Lease.  Subtenant shall not permit any violation of any of the provisions of the Master Lease.  A true and complete copy of the Master Lease is attached hereto as Exhibit C.  If the Master Lease terminates, this Sublease shall terminate, subject to Section 19 below, and the parties shall be relieved from all liabilities and obligations under this Sublease, except that if this Sublease terminates as a result of a default of one of the parties under this Sublease or the Master Lease or both, the defaulting party shall be liable to the non-defaulting party for all damage suffered by the non-defaulting party as a result of termination. In the event of casualty or condemnation, Sublandlord may exercise any right to terminate the Master Lease without regard to this Sublease, and in the event of such a termination, Subtenant shall have no recourse against Sublandlord with respect to such termination.  Sublandlord shall not terminate the Master Lease prior to the expiration of its term without providing Subtenant at least thirty (30) days prior written notice of termination.  In the event Sublandlord receives any notice of failure to pay or failure to perform any covenant, agreement or obligation under the Master Lease, Sublandlord shall notify Subtenant of such notice as soon as the notice is received by Sublandlord pursuant to the terms of the Master Lease and Subtenant may take any such actions to cure any such failure under the Master Lease.  Subtenant shall be under no obligation to take such action but may do so solely at its own discretion.  In the event Subtenant pays any amount or performs any obligations on behalf of Sublandlord pursuant to the terms of the Master Lease, Subtenant may deduct such amounts paid from the amount that would otherwise be due from Subtenant to Sublandlord pursuant to this Sublease. 

19.    Certain rights of Master Landlord and Subtenant.  

(a)    Master Landlord shall have no liability to Subtenant under the Master Lease or this Sublease, and neither the Master Lease nor this Sublease shall be deemed to grant Subtenant any rights against Master Landlord.  

(b)    In the event of Master Lease Termination (as hereinafter defined) during the Sublease term, Subtenant shall, at Subtenant’s option to be exercised in Subtenant’s sole discretion, attorn to Master Landlord and recognize Master Landlord as Subtenant’s landlord under the Master Lease upon the terms and conditions and at the rent specified in the Master Lease to lease the Premises for the then remaining term of the Master Lease and to pay a security deposit to Master Landlord as required by and in accordance with the Master Lease, provided, however, as a condition precedent to Subtenant being required to subordinate its interest in this Sublease and attorn to Master Landlord under the Master Lease, Master Landlord and Subtenant shall execute a non‐disturbance and attornment agreement in a form reasonably satisfactory to Master Landlord and Subtenant, which shall recognize Subtenant’s right to remain in occupancy of and have access to the Premises as long as Subtenant is not in default of the Master Lease beyond applicable notice and cure periods.  Alternatively, if Subtenant does not exercise such option to attorn to Master Landlord under the terms and conditions of the Master Lease and at the rent specified in the Master Lease to lease the Premises as stated above, Master Landlord and Subtenant shall negotiate in good faith to enter into a new lease agreement upon terms and conditions mutually agreeable to Master Landlord and Subtenant. If Subtenant shall attorn to Master Landlord as provided herein, Subtenant agrees to execute and deliver from time to time upon request of Master Landlord any commercially reasonable instruments which may be necessary or appropriate to evidence such attornment.  Master Landlord shall not (i) be liable to Subtenant for any act, omission or breach of this Sublease by Sublandlord, provided that Master Landlord shall be obligated to cure defaults of a continuing nature, (ii) be subject to any offsets or defenses which Subtenant might have against Sublandlord, (iii) be bound by any Base Rent or Additional Rent which Subtenant might have paid in advance to Sublandlord unless actually received by Master Landlord, or (iv) be bound to honor any rights of Subtenant in any security deposit made with Sublandlord except to the extent Sublandlord has turned over such security deposit to Master Landlord.  If Master Landlord and Subtenant mutually do not elect to have Subtenant attorn to Master Landlord either under the Master Lease or upon a new agreement mutually acceptable to Master Landlord and Subtenant, this Sublease shall terminate on the date of Master Lease Termination.  “Master Lease Termination” means any event, voluntary or involuntary or by operation of law, which causes the Master Lease to terminate prior to the end of its stated term.  In the event of an attornment hereunder, Master Landlord’s liability shall be limited to matters arising after such attornment, and shall in all events be limited to the interest of Master Landlord in the property of which the Premises constitutes a part (which interest shall include all rents and profits, insurance proceeds and condemnation awards thereof). 

(c)    In addition to Master Landlord’s rights under paragraph (b) hereof, in the event Sublandlord is in default under the Master Lease, Master Landlord may elect to receive directly from Subtenant all sums due or payable to Sublandlord by Subtenant pursuant to this Sublease, and upon receipt of Master Landlord’s notice, Subtenant shall thereafter pay to Master Landlord any and all sums becoming due or payable under this Sublease. In complying with such direction from Master Landlord, Subtenant shall be entitled to rely solely on such notice from Master Landlord and Sublandlord agrees that Subtenant shall be entitled to full credit under the Sublease for any rents paid to Master Landlord in accordance with the provisions of this Section to the same extent as if such rents were paid directly to Sublandlord. The consent and approval of Sublandlord to this Sublease shall constitute an authorization for Subtenant to make such 

payments to Master Landlord following receipt of such notice and a release and discharge of all liability to Sublandlord for any such payments made to Master Landlord in accordance with this Section.  Neither the service of such written notice nor the receipt of such direct payments shall cause Master Landlord to assume any of Sublandlord’s duties, obligations and/or liabilities under this Sublease, nor shall such event impose upon Master Landlord the duty or obligation to honor this Sublease, nor subsequently to accept Subtenant’s attornment pursuant to paragraph(b) hereof.

20.    Consequential Damages.   Notwithstanding any provision to the contrary contained in this Sublease, under no circumstances shall either party be liable to the other for any injury or damage to, or interference with, the others business, including loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, or for any form of special or consequential damage, though nothing in this Section 20 shall limit or reduce the amount of damages to which Sublandlord is expressly entitled under Section 21 of the Master Lease (as incorporated herein and as applicable to Subtenant defaults) for any Subtenant default .

21.    Execution.  Each individual executing this Sublease on behalf of Sublandlord or Subtenant represents and warrants that he or she has been duly authorized to do so.  

22.    Modification; Successors and Assigns.  This Sublease may only be modified or amended by written agreement executed by each of the parties and consented to by Master Landlord subject to the limitations on transfer provided for by this Sublease.  This Sublease shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.  
23.    Assignment and Subletting.  Subtenant shall not assign this Sublease in whole or in part or sublet the Subleased Premises in whole or in part without the prior written consent of Sublandlord, which may be withheld or conditioned by Sublandlord in Sublandlord’s sole and absolute discretion.  No such sublease or assignment shall be effective without the consent of Master Landlord under the Master Lease.  If, as to any sublease or assignment for which consent is necessary, Subtenant receives rent or other consideration in excess of the Base Rent and Additional Rent payable under this Sublease, Subtenant shall pay to Sublandlord all of such excess, after deducting Subtenant’s reasonable legal and brokerage and fit-up expenses paid for by Subtenant at the time of such subleasing or assignment.  Amounts received by Sublandlord under the immediately preceding sentence shall, after deducting Sublandlord’s reasonable legal expenses incurred in connection therewith, be divided evenly between Master Landlord and Sublandlord.  If Sublandlord and Master Landlord consent to any such assignment or subletting, Subtenant shall remain fully and primarily liable to Sublandlord, in all respects, under this Sublease.
Notwithstanding the foregoing, Sublandlord’s prior written consent shall not be required in connection with an assignment, sublease, transfer and/or use of all or a portion of the Subleased Premises (a “Subtenant Transfer”) by Subtenant to, or by, any entity controlling, controlled by or under common control with Subtenant, or to, or by, any corporation or other entity which is a successor-in-interest to Subtenant by way of merger, consolidation or corporate 

reorganization, or by the purchase of all or substantially all of the assets or the ownership interests of Subtenant; provided that, the terms of this sentence shall not affect or modify the requirement that Subtenant obtain Master Landlord’s prior written consent to all assignments, sublets and Subtenant Transfers. 
24.    Defined Terms.  Capitalized terms used herein and not otherwise defined shall have the meaning ascribed to such terms in the Master Lease.

[Signatures appear on the following page.]

EXECUTED as an instrument under seal as of the day and year first set forth above.

SUBLANDLORD:
    
METABOLIX, INC.,  
a Delaware corporation

By: __________________________________
Name: ________________________________
Title: _________________________________
Date: _________________________________

SUBTENANT:

CJ RESEARCH CENTER LLC

By:  ___________________________________
Name: _________________________________
Title: __________________________________
Date: __________________________________

EXHIBIT A

See attached.

12

EXHIBIT B

Shared Equipment 

13

EXHIBIT C

Master Lease 

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]